About Theron Odlaug
Theron Odlaug has more than 40 years of pharmaceutical industry experience. He advises Signet Healthcare Partners and has worked with its portfolio companies for more than 14 years. He serves on the boards of Ascendia Pharmaceuticals and Pharma Nobis. Odlaug and Gale joined Ascendia's board together. Ascendia offers formulation, analytical and manufacturing services for drug products. He is also president of the Dravet Syndrome Foundation board.
Earlier, Odlaug chaired Impopharma and served as leon-nanodrugs' CEO. He chaired Cedarburg Pharmaceuticals until its 2014 sale. He was Planet Biopharmaceuticals' executive chairman and CEO from 2011 until its 2014 sale. In 2008, he was CyDex's president and chief operating officer. From 2008 to 2011, he was CyDex's president and CEO. Ligand acquired CyDex in 2011. He was a Fujisawa executive vice president and senior management committee member until the 2005 Yamanouchi merger created Astellas. He left Astellas in 2006 after supporting the U.S. integration. Earlier senior roles included Bayer and Baxter. He also served on leon-nanodrugs' supervisory board. He served on CoreRx's board until its 2021 sale to NovaQuest.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Theron Odlaug in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Theron Odlaug works with at each company, as listed on that company's latest Form D.